WO2007132478A2 - Process for the preparation of pure risedronic acid or salts - Google Patents

Process for the preparation of pure risedronic acid or salts Download PDF

Info

Publication number
WO2007132478A2
WO2007132478A2 PCT/IN2007/000187 IN2007000187W WO2007132478A2 WO 2007132478 A2 WO2007132478 A2 WO 2007132478A2 IN 2007000187 W IN2007000187 W IN 2007000187W WO 2007132478 A2 WO2007132478 A2 WO 2007132478A2
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorous
acid
formula
risedronic acid
reaction mass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2007/000187
Other languages
French (fr)
Other versions
WO2007132478A3 (en
Inventor
Rahul Saxena
Anshul Kumar Jain
Chidambaram Ventakeswaran Srinivasan
Lalit Wadhwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IND-SWIFT LABORATORIES Ltd
Ind Swift Laboratories Ltd
Original Assignee
IND-SWIFT LABORATORIES Ltd
Ind Swift Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IND-SWIFT LABORATORIES Ltd, Ind Swift Laboratories Ltd filed Critical IND-SWIFT LABORATORIES Ltd
Priority to JP2009508675A priority Critical patent/JP2009536639A/en
Priority to MX2008014248A priority patent/MX2008014248A/en
Priority to BRPI0710421-9A priority patent/BRPI0710421A2/en
Priority to US12/299,615 priority patent/US8076483B2/en
Priority to EP07736604A priority patent/EP2016084A2/en
Publication of WO2007132478A2 publication Critical patent/WO2007132478A2/en
Anticipated expiration legal-status Critical
Publication of WO2007132478A3 publication Critical patent/WO2007132478A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Definitions

  • the present invention relates to a process for the preparation of bisphosphonic acid in particular risedronic acid or its pharmaceutically acceptable salt, useful in the treatment of bone disorders. More particularly, the present invention relates to a novel method for the preparation of risedronic acid, namely, [l-hydiOxy-2(3-pyridinyl)ethylidene] bisphosphonic acid having Formula-I or its salts in high purity and high yield.
  • the bisphosponates which are salts of bisphosphonic acids, are an important class of medicaments useful in the treatment of bone disorders such as Paget's disease and osteoporosis.
  • the bisphosphonates for example etidronate, pamidronate, and risedronate are used in the form of various non-toxic and pharmaceutically acceptable esters, alkali metal salts and salts of alkaline-earth metals and their various hydrates.
  • the form of the substance can have a fundamental influence on its solubility and its biological availability.
  • the preferred forms of risedronate are the sodium and calcium salts.
  • Risedronic acid chemically known as [l-hydiOxy-2(3-pyridinyl)ethylidene] bisphosphonic acid, presently marketed as risedronate sodium under the tradename Actonel, is an important active pharmaceutical ingredient for the treatment of osteoporosis.
  • reaction when the reaction is carried out in chlorobenzene as a diluent, it does not solubilize the reaction components.
  • the reaction starts as a two phase system, in which the melt gradually thickens into a non-stirrable mass. This semisolid sticky mass finally turns into a hard, rigid material coated on the walls of the reaction vessel which is preventing smooth heat transfer.
  • the process might be suitable for laboratory preparation of gram quantities of the product; however, for industrial production it is not acceptable and is not reasonable even for a modest scale up.
  • US Patent 6,562,974 discloses a process for the preparation of geminal bisphosphonate using pyridine hydrochloride, morpholine hydrochloride & phosphoric acid at 7O 0 C.
  • US Patent application 2004/0043967A1 discloses a process for the preparation of risedronate comprising the use of aromatic hydrocarbon or a silicone fluid optionally with poly-alkene glycol.
  • these solvents have a high cost and are difficult to eliminate from the finished product
  • PCT application WO 03/93282 Al describes a process for the preparation of risedronate & its monovalent cation using ionic liquid (ti ⁇ -butyl ammonium chloride) as solvent at 15-120 0 C.
  • ionic liquid ti ⁇ -butyl ammonium chloride
  • the disclosed invention uses a solvent which is an expensive reagent, difficult to recover. Also, the yields reported are very low.
  • PCT application WO 05/044831A2 describes a process for the preparation of risedronic acid by using sulfolane as reaction solvent. Quenching of the reaction mixture containing sulfolane. with water causes high exothermicity and reaction becomes uncontrollable, hence is difficult to handle.
  • PCT application WO05/63779A2 describes a process for the preparation of risedronate using a mixture of phosphorous acid & phosphorous chloride in the absence of solvent. Requirement of more reaction time and large quantities of reactants for the reaction makes the process inefficient and expensive for use on a large scale. Also, the yields obtained are very low.
  • the present invention provides an industrially advantageous process for preparation of risedronic acid or salts, chemically known as [l-hydroxy-2(3 ⁇ pyridinyl)ethylidene] bisphosphonic acid, of formula-! in high purity and high yields.
  • the present invention provides improved processes for preparing risedronic acid and risedronic acid monosodium salt.
  • risedronic acid or salts preferably monosodium salt can be prepared by one pot process comprising reacting carboxylic acid compound in particular 3-pyridyl acetic acid with phosphorous acid in the presence of phosphorous halide in a water miscible neutral solvent such as acetonitrile, optionally distilling the solvent, quenching the reaction mixture with water, adjusting the pH using sodium source and isolating pure risedronic acid monosodium salt in high yield and purity.
  • a water miscible neutral solvent such as acetonitrile
  • the present invention provides an efficient, economic and also environmentally friendly process which comprises obtaining the risedronic acid by reacting carboxylic acid compound in particular 3-pyridyl acetic acid with phosphorous acid in the presence of phosphorous halide in a water miscible neutral solvent such as acetonitrile, optionally distilling the solvent, quenching the reaction mixture with water. Thereafter risedronic acid is converted to risedronic acid mono sodium salt by the methods reported in the prior art.
  • Yet another embodiment of the present invention provides a process for the preparation of risedronic acid using chlorobenzene, avoiding decantation and isolation of the pure product by a simple layer separation method.
  • the present invention provides a process for the preparation of risedronic acid or salts of formula- ⁇ ,
  • the present invention relates to a safe mode of preparing risedronic acid, in high yields and high purity.
  • the present invention uses acetonitrile, which is a water miscible neutral solvent, relatively safe and inexpensive.
  • acetonitrile which is a water miscible neutral solvent, relatively safe and inexpensive.
  • 3-pyridyl acetic acid of formula II and the phosphorous acid in acetonitrile are reacted with phosphorous halide at temperature 40-80°C, and preferably at about 70-75 0 C till phosphonylation is complete.
  • Phosphorous halide can be selected from the group comprising phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide and the like.
  • 3-pyridyl acetic acid of formula II and the phosphorous acid in acetonitrile are reacted with phosphorous trichloride.
  • phosphorous trichloride is added in small portions.
  • the reaction mixture is refluxed to a temperature of 70 ⁇ 5°C for a period of about 1 to about 12 hours till phosphonylation is complete.
  • acetonitrile is distilled off completely. The acetonitrile so recovered by distillation can be reused, thus making the process more economical and cost effective.
  • the reaction mixture is quenched at ambient temperature with demineralized water.
  • the substrate is effective to treat the substrate with an adsorbent, preferably with active charcoal.
  • the filtered mass is further refluxed for a period of about 1 to about 12 hours at a temperature of 85 ⁇ 5°C till complete hydrolysis.
  • the reaction mixture is cooled to 0-5°C and stirred for a period of 2-3 hours.
  • risedronic acid is filtered and washed with demineralized water.
  • Risedronic acid prepared can be optionally purified by acid base treatment like risedronic acid in water is treated with base to adjust pH above seven and further treatment with mineral acid to bring pH at 1-2.
  • risedronic acid in high yields and better quality as compared to any of the prior art processes. Thereafter risedronic acid is converted to risedronic acid monosodium salt by the methods reported in the prior art.
  • the process for preparing risedronic acid monosodium salt comprises suspending the risedronic acid formed in demineralized water and pH is suitably adjusted to 4.2-4.5 with a base selected from alkali carbonates, alkali hydroxides or alkali bicarbonates.
  • a base selected from alkali carbonates, alkali hydroxides or alkali bicarbonates.
  • the base employed is sodium hydroxide, preferably 50% sodium hydroxide.
  • the precipitated salt may be isolated by a manner well known in art.
  • the present invention provides a one pot process for the preparation of risedronic acid mono sodium salt of formula-TIT,
  • 3-pyridyl acetic acid of formula TT and the phosphorous acid are reacted in a suitable solvent like acetonitrile at reflux temperature.
  • Phosphorous halide is slowly added to the above reaction mixture at a temperature of 40-100 0 C, preferably at about 70 ⁇ 5 'J C till phosphonylation is complete.
  • Phosphorous halide can be selected from amongst phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide and the like and preferably phosphorous trichloride is used.
  • reaction mass After distillation, the filtered mass is cooled to ambient temperature preferably 25 ⁇ 2°C and reaction mass is quenched with water. The resultant reaction mass is then charcoalised to decolorize the reaction mass.
  • reaction mass is refluxed for a period of about 1 to 12 hours to complete hydrolysis.
  • risedronic acid is converted to monosodium salt.
  • the preparation of sodium salt is pH dependent, from about pH 3.0 to about pH 12.0.
  • the pH is adjusted to 4.3 to obtain the mono sodium salt using a suitable base.
  • the base can be selected from alkali carbonates, alkali hydroxides or alkali bicarbonates.
  • the base employed is sodium hydroxide and more preferably 50% sodium hydroxide.
  • reaction mass is directly basified with sodium hydroxide at a pH of 4.2-4.5.
  • reaction mass is first basified with sodium hydroxide at a pH of 8-9 and then acidified with concentrated hydrochloric acid to bring the pH to 4.2-4.5.
  • the reaction mass is initially cooled to ambient temperature and finally to a temperature of below 5 0 C. Thereafter the product can be isolated from the reaction mixture by the methods known in prior art such as filtration.
  • reaction mixture After completion of reaction, the reaction mixture is cooled to a temperature below 50°C and demineralized water is added slowly. The reaction mass is stirred for a period of about 30 minutes and allow the layers to settle and separate. The organic layer is then extracted with demineralized water. The combined aqueous layer is charcoalised to decolorize the reaction mass. The filtered mass is refluxed azeotropically for a period of about 1 to 12 hours to complete hydrolysis and removal of traces of chlorobenzene. The reaction mass is then cooled to ambient temperature. Thereafter the product can be isolated from the reaction mixture by the methods known in prior art such as Filtration. The product obtained is highly pure having purity greater than 97% by high performance liquid chromatography (HPLC) and yield is above 80%.
  • HPLC high performance liquid chromatography
  • the reaction mass was cooled to ambient temperature and then to 0-5 0 C and stirred further for 2.0 hour.
  • the solid was filtered, washed with 20% aqueous ethyl alcohol to get the pure risedronate sodium (33 g ) having purity of 99.24% by HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to an industrially advantageous process of making bisphosphonic acid or its salt in particular risedronic acid, [l-hydroxy-2(3-pyridinyl)ethylidene] bisphosphonic acid, having formula-(I) or its salts in high purity and high yields.

Description

PROCESS FOR THE PREPARATION QF PURE RISEDRONIC ACIP OR SALTS
FIELD OF INVENTION
The present invention relates to a process for the preparation of bisphosphonic acid in particular risedronic acid or its pharmaceutically acceptable salt, useful in the treatment of bone disorders. More particularly, the present invention relates to a novel method for the preparation of risedronic acid, namely, [l-hydiOxy-2(3-pyridinyl)ethylidene] bisphosphonic acid having Formula-I or its salts in high purity and high yield.
Figure imgf000002_0001
Formula-!
BACKGROUND OF THE INVENTION
The bisphosponates, which are salts of bisphosphonic acids, are an important class of medicaments useful in the treatment of bone disorders such as Paget's disease and osteoporosis.
The bisphosphonates, for example etidronate, pamidronate, and risedronate are used in the form of various non-toxic and pharmaceutically acceptable esters, alkali metal salts and salts of alkaline-earth metals and their various hydrates. The form of the substance can have a fundamental influence on its solubility and its biological availability. The preferred forms of risedronate are the sodium and calcium salts. Risedronic acid, chemically known as [l-hydiOxy-2(3-pyridinyl)ethylidene] bisphosphonic acid, presently marketed as risedronate sodium under the tradename Actonel, is an important active pharmaceutical ingredient for the treatment of osteoporosis.
Risedronic acid and its pharmaceutically acceptable salts were first disclosed in US Patent 5,583,122, US patent 5,583,122 discloses risedronic acid, but its preparation is not exemplified. On the contrary, the patent discloses the synthesis of an isomer, l-hydroxy-2-(2-pyπdyl)-l,l-diphosρhonic acid, by reaction of (2-pyridyl) acetic acid with phosphorous acid and phosphorus trichloride in chlorobenzene. At the end of the reaction, the mixture solidifies and the solvent is removed by decantation.
But as described, when the reaction is carried out in chlorobenzene as a diluent, it does not solubilize the reaction components. The reaction starts as a two phase system, in which the melt gradually thickens into a non-stirrable mass. This semisolid sticky mass finally turns into a hard, rigid material coated on the walls of the reaction vessel which is preventing smooth heat transfer. The process might be suitable for laboratory preparation of gram quantities of the product; however, for industrial production it is not acceptable and is not reasonable even for a modest scale up.
US Patent 5,908,959 teaches use of long chain glycols to attempt to prevent the solidification of the reaction mixture, however the solidification cannot be totally avoided and these glycols cannot be recycled as they get converted to their corresponding chloride derivatives, which could be potentially toxic.
US Patent 5,648,491 discloses the use of methanesulfonic acid as reaction solvent. However, this technique involves the risk of safety as this solvent gives rise to uncontrollable reactions in the reaction conditions, when the temperature of the reacting mixture exceeds 85 "C. Also, methanesulfonic acid is corrosive to skin, irritant and quite expensive.
US Patent 6,562,974 discloses a process for the preparation of geminal bisphosphonate using pyridine hydrochloride, morpholine hydrochloride & phosphoric acid at 7O0C. US Patent application 2004/0043967A1 discloses a process for the preparation of risedronate comprising the use of aromatic hydrocarbon or a silicone fluid optionally with poly-alkene glycol. However, these solvents have a high cost and are difficult to eliminate from the finished product
because of their high boiling point. Also, large quantities of poly-alkene glycol are required for the reaction, making it inefficient for use on a large scale.
PCT application WO 03/93282 Al describes a process for the preparation of risedronate & its monovalent cation using ionic liquid (tiϊ-butyl ammonium chloride) as solvent at 15-1200C. The disclosed invention uses a solvent which is an expensive reagent, difficult to recover. Also, the yields reported are very low. ]
PCT application WO 05/044831A2 describes a process for the preparation of risedronic acid by using sulfolane as reaction solvent. Quenching of the reaction mixture containing sulfolane. with water causes high exothermicity and reaction becomes uncontrollable, hence is difficult to handle.
PCT application WO05/63779A2 describes a process for the preparation of risedronate using a mixture of phosphorous acid & phosphorous chloride in the absence of solvent. Requirement of more reaction time and large quantities of reactants for the reaction makes the process inefficient and expensive for use on a large scale. Also, the yields obtained are very low.
It is evident from prior art that different processes known for the preparation of risedronic acid and its pharmaceutically acceptable salts have some disadvantages associated with their use. So, there is an urgent need to develop a process for the preparation of risedronic acid or its salts that may overcome the drawbacks of prior art processes and should be industrially viable.
Accordingly, it is an object of the present invention to provide an efficient, safe and convenient process for preparation of risedronic acid wherein a water miscible neutral solvent such as acetonitrile is used and is further converted to risedronic acid monosodium salt in high yield and purity SUMMARY OF THE PRESENT INVENTION
The present invention provides an industrially advantageous process for preparation of risedronic acid or salts, chemically known as [l-hydroxy-2(3~pyridinyl)ethylidene] bisphosphonic acid, of formula-! in high purity and high yields.
Figure imgf000005_0001
Formula-I
More particularly, the present invention provides improved processes for preparing risedronic acid and risedronic acid monosodium salt.
In one embodiment of the present invention, risedronic acid or salts preferably monosodium salt can be prepared by one pot process comprising reacting carboxylic acid compound in particular 3-pyridyl acetic acid with phosphorous acid in the presence of phosphorous halide in a water miscible neutral solvent such as acetonitrile, optionally distilling the solvent, quenching the reaction mixture with water, adjusting the pH using sodium source and isolating pure risedronic acid monosodium salt in high yield and purity.
In another embodiment, the present invention provides an efficient, economic and also environmentally friendly process which comprises obtaining the risedronic acid by reacting carboxylic acid compound in particular 3-pyridyl acetic acid with phosphorous acid in the presence of phosphorous halide in a water miscible neutral solvent such as acetonitrile, optionally distilling the solvent, quenching the reaction mixture with water. Thereafter risedronic acid is converted to risedronic acid mono sodium salt by the methods reported in the prior art. Yet another embodiment of the present invention provides a process for the preparation of risedronic acid using chlorobenzene, avoiding decantation and isolation of the pure product by a simple layer separation method.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description is provided herein to aid the persons skilled in the art in practicing the present invention. Even so, this detailed description should not be construed to unduly limit the present invention as modifications and variations in the embodiments discussed herein can be made by those of ordinary skill in the art without departing from the spirit or scope of the present inventive discovery.
Accordingly, the present invention provides a process for the preparation of risedronic acid or salts of formula-ϊ,
Figure imgf000006_0001
Formula-I
by reacting a carboxylic acid in particular 3-pyridyl acetic acid of formula-II,
Figure imgf000006_0002
Formula-II
with phosphorous acid and phosphorous halide in a suitable solvent like acetonitiϊle.
The present invention relates to a safe mode of preparing risedronic acid, in high yields and high purity. The present invention uses acetonitrile, which is a water miscible neutral solvent, relatively safe and inexpensive. According to detailed embodiment of the present invention, 3-pyridyl acetic acid of formula II and the phosphorous acid in acetonitrile are reacted with phosphorous halide at temperature 40-80°C, and preferably at about 70-750C till phosphonylation is complete. Phosphorous halide can be selected from the group comprising phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide and the like.
Particularly, 3-pyridyl acetic acid of formula II and the phosphorous acid in acetonitrile are reacted with phosphorous trichloride. To the reaction mixture at temperature of about 70±5"C, phosphorous trichloride is added in small portions. The reaction mixture is refluxed to a temperature of 70±5°C for a period of about 1 to about 12 hours till phosphonylation is complete. Optionally, acetonitrile is distilled off completely. The acetonitrile so recovered by distillation can be reused, thus making the process more economical and cost effective. The reaction mixture is quenched at ambient temperature with demineralized water.
In yet another embodiment of the present invention, to assist in impurity removal, it is effective to treat the substrate with an adsorbent, preferably with active charcoal. The filtered mass is further refluxed for a period of about 1 to about 12 hours at a temperature of 85±5°C till complete hydrolysis. The reaction mixture is cooled to 0-5°C and stirred for a period of 2-3 hours.
In a preferred embodiment of the present invention the risedronic acid is filtered and washed with demineralized water. Risedronic acid prepared can be optionally purified by acid base treatment like risedronic acid in water is treated with base to adjust pH above seven and further treatment with mineral acid to bring pH at 1-2.
It is observed that the process of the present invention provides risedronic acid in high yields and better quality as compared to any of the prior art processes. Thereafter risedronic acid is converted to risedronic acid monosodium salt by the methods reported in the prior art.
Particularly, the process for preparing risedronic acid monosodium salt comprises suspending the risedronic acid formed in demineralized water and pH is suitably adjusted to 4.2-4.5 with a base selected from alkali carbonates, alkali hydroxides or alkali bicarbonates. In the preferred embodiment of the present invention, the base employed is sodium hydroxide, preferably 50% sodium hydroxide. The precipitated salt may be isolated by a manner well known in art.
According to another embodiment, the present invention provides a one pot process for the preparation of risedronic acid mono sodium salt of formula-TIT,
Figure imgf000008_0001
Formula-Ill
by reacting carboxylic acid in particular 3-pyridyl acetic acid of formula-II,
Figure imgf000008_0002
Formula-II
with phosphorous acid and phosphorous halide in a suitable solvent, quenching the reaction with water and optionally distilling off the solvent, adjusting the pH using sodium source and isolating the highly pure risedronic acid monosodium salt in high yield and purity.
According to detailed embodiment of the present invention, 3-pyridyl acetic acid of formula TT and the phosphorous acid are reacted in a suitable solvent like acetonitrile at reflux temperature. Phosphorous halide is slowly added to the above reaction mixture at a temperature of 40-1000C, preferably at about 70±5'JC till phosphonylation is complete. Phosphorous halide can be selected from amongst phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide and the like and preferably phosphorous trichloride is used.
When the phosphonylation is complete, the solvent is distilled off. As discussed earlier, distillation is not a must step here as presence of acetonitrile doesn't interferes with the course of the reaction.
After distillation, the filtered mass is cooled to ambient temperature preferably 25±2°C and reaction mass is quenched with water. The resultant reaction mass is then charcoalised to decolorize the reaction mass.
The reaction mass is refluxed for a period of about 1 to 12 hours to complete hydrolysis. After hydrolysis, risedronic acid is converted to monosodium salt. The preparation of sodium salt is pH dependent, from about pH 3.0 to about pH 12.0. Preferably, the pH is adjusted to 4.3 to obtain the mono sodium salt using a suitable base.
The base can be selected from alkali carbonates, alkali hydroxides or alkali bicarbonates. In the preferred embodiment of the present invention, the base employed is sodium hydroxide and more preferably 50% sodium hydroxide.
The reaction can be further preceded in two ways. According to one embodiment of the present invention, the reaction mass is directly basified with sodium hydroxide at a pH of 4.2-4.5. According to another embodiment of the present invention, the reaction mass is first basified with sodium hydroxide at a pH of 8-9 and then acidified with concentrated hydrochloric acid to bring the pH to 4.2-4.5.
The reaction mass is initially cooled to ambient temperature and finally to a temperature of below 5 0C. Thereafter the product can be isolated from the reaction mixture by the methods known in prior art such as filtration.
According to yet another embodiment of the present invention there is provided a process for the isolation of pure risedronic acid from the reaction mixture wherein 3-ρyridyl acetic acid is reacted with phosphorous acid and phosphorous trichloride in chlorobenzene. acid in chlorobenzene are reacted with phosphorous trichloride at a suitable temperature, preferably at about 90±5°C till phosphorylation is complete as reported in US patent 5,583,122.
After completion of reaction, the reaction mixture is cooled to a temperature below 50°C and demineralized water is added slowly. The reaction mass is stirred for a period of about 30 minutes and allow the layers to settle and separate. The organic layer is then extracted with demineralized water. The combined aqueous layer is charcoalised to decolorize the reaction mass. The filtered mass is refluxed azeotropically for a period of about 1 to 12 hours to complete hydrolysis and removal of traces of chlorobenzene. The reaction mass is then cooled to ambient temperature. Thereafter the product can be isolated from the reaction mixture by the methods known in prior art such as Filtration. The product obtained is highly pure having purity greater than 97% by high performance liquid chromatography (HPLC) and yield is above 80%. Thus, layer separation method described in the present course of reaction overcomes the drawbacks of the prior art processes and hence provides an industrially reproducible route even by using chlorobenzene.
Major advantages realized in the present invention are increased process productivity and product purity. The process of the present invention is feasible commercially and simple on industrial scale. Direct conversion of 3-pyridyl acetic acid into risedronic acid monosodium salt without the isolation of risedronic acid results in reducing the time cycle of the reaction, avoiding complicated separation or purification steps and reducing expenditure on equipment, hence makes the process industrially advantageous and cost effective.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the inventions and is not intended to limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES
Example-1
Preparation of Risedronic acid
3 -Pyridine acetic acid (100 g) was added to acetonitrile (1.0 L). To the reaction mixture was added phosphorous acid (142 g). The reaction mass was heated up to reflux temperature (70-750C). To this phosphorous trichloride (271 g) was added slowly and the reaction mass was refluxed for 5.0 hours.
The solvent was distilled off completely under vacuum. Demineralized water (400 ml) was added to the reaction mass at ambient temperature and charcoalised. The filtered mass was refluxed for 4.0 hours at 850C. The reaction mass was cooled to 0-50C and stirred for 2 hours. It was filtered and washed with demineralized water to get risedronic acid (175 g, yield 84.58 %) as a white crystalline solid having purity of 98.59% by HPLC.
Example-2
Preparation of Risedronic acid Monosodium Salt
3 -Pyridine acetic acid (100 g) added to acetonitrile(1.0 L). To the reaction mixture was added phosphorous acid (142 g). The reaction mass was heated up to reflux temperature (70-750C). To this phosphorous trichloride (271 g) was added slowly at 7O0C and the reaction mass was refluxed for 5.0 hours. The solvent was distilled off completely under vacuum, Demineralized water (400 ml) was added to the reaction mass at ambient temperature and charcoalised. The filtered mass was refluxed for 4.0 hours at 850C. The reaction mass was cooled to 0-50C and stirred for 2 hours. It was filtered and washed with demineralized water to get risedronic acid as a white crystalline solid. The wet material was dissolved in demineralized water (300 ml) and 50% sodium hydroxide solution was added to reaction mass to make the pH basic, charcoalised and acidified with concentrated hydrochloric acid. The reaction mass was stirred further for 1.0 hour. The solid was filtered, washed with demineralized water to get the pure risedronic acid (160 g, yield 77.33 %) having purity of 99.25% by HPLC. Preparation of Risedronic Acid Mono Sodium Salt
3-Pyridine acetic acid (25 g) was added to acetonitrile (250 ml). To the reaction mixture was added phosphorous acid (35.5 g). The reaction mass was heated up to reflux temperature (70-750C). To this - phosphorous trichloride (58.97 g) was added slowly and the reaction mass was refluxed for 5.0 hours. The solvent was distilled off completely under vacuum. Demineralized water (100 ml) was added to the reaction mass at ambient temperature and cliarcoalised. The filtered mass was refluxed for 4-5 hours at 850C. The reaction mass was cooled to ambient temperature. 50% sodium hydroxide solution was added to reaction mass to make the pH basic, cliarcoalised and acidified with concentrated hydrochloric acid to pH 4.2-4.5. The reaction mass was cooled to ambient temperature and then to 0- 50C and stirred further for 2.0 hour. The solid was filtered, washed with 20% aqueous ethyl alcohol to get the pure risedronate sodium (5 Ig ) having purity of 99.66% by HPLC.
Example-4
Preparation of Risedronic Acid Mono Sodium Salt
3 -Pyridine acetic acid (25 g) was added to acetonitrile (250 ml). To the reaction mixture was added phosphorous acid (35.5 g). The reaction mass was heated up to reflux temperature (70-750C). To this phosphorous trichloride (58.97 g) was added slowly and the reaction mass was refluxed for 5.0 hours. The solvent was distilled off completely under vacuum. Demineralized water (100 ml) was added to the reaction mass at ambient temperature and cliarcoalised. The filtered mass was refluxed for 4-5 hours at 850C. The reaction mass was cooled to 50-60 0C. 50% sodium hydroxide solution was added to reaction mass to make the pH 4.2-4.5. The reaction mass was cooled to ambient temperature and then to 0-50C and stirred further for 2.0 hour. The solid was filtered, washed with 20% aqueous ethyl alcohol to get the pure risedronate sodium (33 g ) having purity of 99.24% by HPLC.
Example-5
Preparation of Risedronic acid
3 -Pyridine acetic acid (25 g) added to cliloro benzene (250 ml). To the reaction mixture was added phosphorous acid (35.50 g). The reaction mass was heated up to 85-9O0C. To this phosphorous 950C and cooled to 250C. To the reaction mass demineralized water was added slowly at ambient temperature. The reaction mass was stirred for 30 minutes. The layers were allowed to settle and separate. The organic layer was extracted with demineralized water (50 ml). The combined aqueous layer was charcoalised and the filtered mass was refluxed azeotropically for 12 hours. The reaction mass was cooled to ambient temperature, filtered and washed with demineralized water (50 ml) to get risedronic acid (41.5g, yield 80.22 %) having purity of 97.53 % by HP
Reference Example
Preparation of Risedronic acid
3-Pyridine acetic acid (25 g) in 500 ml of chlorobenzene added to phosphorous acid (35.5 g). The reaction mixture was heated up to 85-9O0C. To the reaction mixture phosphorous trichloride (58.97 g) was added slowly to obtain a yellowish rigid, thick mass. The reaction mass was cooled to ambient temperature. The solvent was decanted. Demineralized water (200 ml) was added to the reaction mass and refluxed azeotropically, to remove residual chlorobenzene. Filtered through hyflo bed while hot, washed with hot demineralized water. The reaction mass was cooled to 0-50C, stirred for 1.0 hour, filtered the solid and washed to get risedronic acid (30.0 g, yield 58%) having purity of 83.98% by HPLC.

Claims

1. A process for the preparation of risedronic acid of Formula I or its salts,
Figure imgf000014_0001
Formula-I
comprises,
reacting carboxylic acid compound of formula -II,
Figure imgf000014_0002
Formula-TT
with phosphorous acid and phosphorous halide in a water miscible neutral solvent, at a temperature of 40-800C, quenching the reaction mass with water, refluxing the reaction mixture for sufficient time to complete hydrolysis, isolating pure risedronic acid and converting to risedronic acid mono sodium salt by treating with a suitable base.
2. A process according to claim 1, wherein the water miscible neutral solvent used during phosphonylation is acetonitrile.
3. A process according to claim 1 , wherein the phosphorous halide is selected from the group comprising phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide.
4. A process according to claim 1 , wherein the water is added to the reaction mass for quenching after the complete distillation of the solvent.
5. A process according to claim 1, wherein the water is added to the reaction mass for quenching without the recovery of the solvent.
6. A one step process for the preparation of risedronic acid mono sodium salt of Formula III,
Figure imgf000015_0001
F^rmula-TTT
comprises
reacting carboxylic acid compound of formula -II,
Figure imgf000015_0002
Formula-II
with phosphorous acid and phosphorous halide in a solvent, at a temperature of 40~80"C, quenching the reaction mass with water, refluxing the reaction mixture for sufficient time to complete hydrolysis, treating the reaction mixture with base and isolating risedronic acid sodium salt.
7. A process according to claim 6, wherein the solvent used during phosphorylation is acetonitrile.
8. A process according to claim 6, wherein the phosphorous halide is selected from the group comprising phosphorous trichloride, phosphorous tribromide, phosphorous pentachloride, phosphorous pentabromide, phosphorous oxychloride, phosphorous oxybromide.
9. A process according to claim 6, wherein the base is selected from alkali metal carbonates, alkali metal hydroxides or alkali metal bicarbonates.
10. A process for the preparation of risedronic acid of Formula I,
Figure imgf000016_0001
Formula-I
comprises,
reacting carboxylic acid compound of formula -II,
Figure imgf000016_0002
Forniula-II
with phosphorous acid and phosphorous halide in chlorobenzene, quenching the reaction mass with water at ambient temperature, separating the layers, refluxing the aqueous layer for sufficient time to complete hydrolysis and isolating pure risedronic acid by filteration.
PCT/IN2007/000187 2006-05-11 2007-05-09 Process for the preparation of pure risedronic acid or salts Ceased WO2007132478A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009508675A JP2009536639A (en) 2006-05-11 2007-05-09 Process for preparing pure risedronic acid or salt
MX2008014248A MX2008014248A (en) 2006-05-11 2007-05-09 Process for the preparation of pure risedronic acid or salts.
BRPI0710421-9A BRPI0710421A2 (en) 2006-05-11 2007-05-09 process for the preparation of pure risedronic acid or salts
US12/299,615 US8076483B2 (en) 2006-05-11 2007-05-09 Process for the preparation of pure risedronic acid or salts
EP07736604A EP2016084A2 (en) 2006-05-11 2007-05-09 Process for the preparation of pure risedronic acid or salts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1177/DEL/2006 2006-05-11
IN1177DE2006 2006-05-11

Publications (2)

Publication Number Publication Date
WO2007132478A2 true WO2007132478A2 (en) 2007-11-22
WO2007132478A3 WO2007132478A3 (en) 2009-06-04

Family

ID=38694309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000187 Ceased WO2007132478A2 (en) 2006-05-11 2007-05-09 Process for the preparation of pure risedronic acid or salts

Country Status (7)

Country Link
US (1) US8076483B2 (en)
EP (1) EP2016084A2 (en)
JP (1) JP2009536639A (en)
KR (1) KR20090005206A (en)
BR (1) BRPI0710421A2 (en)
MX (1) MX2008014248A (en)
WO (1) WO2007132478A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041148A1 (en) * 2006-07-03 2009-04-01 Generics Ýuk¨Limited Novel process for the preparation of bisphosphonic acids
JP2009269867A (en) * 2008-05-08 2009-11-19 Daito Kk Method for industrially producing risedronic acid
CN104418886A (en) * 2013-09-02 2015-03-18 河南天方药业股份有限公司 Risedronic acid synthesized by one-pot process

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050731A2 (en) * 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (en) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf METHOD FOR PRODUCING OMEGA-AMINO-1-HYDROXYALKYLIDEN-1,1-BIS-PHOSPHONIC ACIDS
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW257765B (en) 1993-08-25 1995-09-21 Merck & Co Inc
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
CA2197267C (en) 1997-02-11 2000-02-08 Yong Tao Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
ES2153794B1 (en) * 1999-08-06 2001-10-16 Medichem Sa PROCEDURE FOR OBTAINING THE 4-AMINO-1-HYDROXIBUTILIDEN-1,1-BISPHOSPHONIC ACID AND ITS TRIHYDRATED MONOSODIC SALT.
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
PE20011061A1 (en) 2000-02-01 2001-11-20 Procter & Gamble SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE
GB0115824D0 (en) * 2001-06-28 2001-08-22 Rhodia Cons Spec Ltd Improved solvent systems
HRP20041051A2 (en) 2002-04-11 2005-02-28 Teva Pharmaceutical Industries Ltd. Novel polymorphs and pseudopolymorphs of risedronate sodium
ITMI20020908A1 (en) 2002-04-29 2003-10-29 Chemi Spa ALENDRONATE SODIUM PREPARATION PROCESS
EP1476451B1 (en) * 2002-05-17 2010-03-17 Teva Pharmaceutical Industries Ltd. Use of certain diluents for making bisphosphonic acids
CZ293349B6 (en) 2002-10-25 2004-04-14 Léčiva, A.S. Novel crystalline form of 3-pyridyl-1-hydroxyethylidene-1,1-bisphopshonoc acid sodium salt
ES2311142T3 (en) 2003-01-17 2009-02-01 Teva Pharmaceutical Industries Limited PROCEDURE TO REDUCE THE IRON CONTENT OF SODIUM RISEDRONATE.
HUP0300227A2 (en) 2003-01-28 2004-09-28 Richter Gedeon Vegyészeti Gyár Rt. Process for preparing 2-substituted-1-hidroxyetylidene-1,1-bisphosphonic acids and their salts with high purity
BRPI0413067A (en) 2003-07-30 2006-10-17 Procter & Gamble process to control the crystal structure of risedronate
JP4642762B2 (en) 2003-08-21 2011-03-02 サン・ファーマシューティカル・インダストリーズ・リミテッド Method for producing bisphosphonic acid compound
DE602004032577D1 (en) 2003-12-23 2011-06-16 Alchymars S P A Amorphous form the sodium salt of ibandronic acid
WO2005066190A1 (en) 2004-01-02 2005-07-21 Hexal A/S New risedronate salts
CZ298639B6 (en) 2004-02-05 2007-12-05 Zentiva, A. S. Crystalline form of monosodium risedronate
US7618953B2 (en) 2004-02-26 2009-11-17 Zentiva, A.S. Amorphous forms of risedronate monosodium
DE602005001873T2 (en) 2004-03-03 2008-04-24 Chemi S.P.A., Cinisello Balsamo Amorphous 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid monosodium salt and process for its preparation
US7361761B2 (en) 2004-09-28 2008-04-22 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of bisphosphonic acid
WO2006051553A1 (en) 2004-11-09 2006-05-18 Jubilant Organosys Limited Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt
PL199215B1 (en) 2004-12-28 2008-08-29 Politechnika Gdanska Method for the manufacture of [1-hydroxy-2-(3-pyridyl) ethylidene bis-phosphonic] acid and its 2 and a half aqueous monosodium salt
US20080194525A1 (en) 2005-05-06 2008-08-14 Jordi Puig Serrano Process of Making Geminal Bisphosphonic Acids and Pharmaceutically Acceptable Salts and/or Hydrates Thereof
EP1888606A2 (en) 2005-05-28 2008-02-20 PLIVA HRVATSKA d.o.o. Process and novel salt
US7872144B2 (en) 2005-06-13 2011-01-18 Jubilant Organosys Limited Process for producing biphosphonic acids and forms thereof
WO2007026379A2 (en) 2005-08-30 2007-03-08 Natco Pharma Limited Novel crystalline forms of risedronate monosodium
GB0519891D0 (en) 2005-09-30 2005-11-09 Pliva Hrvatska D O O Pharmaceutically acceptable salts and hydrates
WO2007042048A2 (en) 2005-10-11 2007-04-19 Sandoz A/S Method for preparing crystalline sodium risedronate
US8003820B2 (en) 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
WO2007083240A2 (en) 2006-01-20 2007-07-26 Aurobindo Pharma Limited An improved process for the preparation of bisphosphonic acids
WO2007083243A2 (en) 2006-01-20 2007-07-26 Aurobindo Pharma Limited An improved process for the preparation of risedronate sodium hemi-pentahydrate
WO2007096896A1 (en) 2006-02-20 2007-08-30 Alembic Limited An improved process for the preparation of biphosphonic derivatives
GB0609465D0 (en) 2006-05-12 2006-06-21 Pliva Hrvatska D O O Pharmaceutically acceptable salts and polymorphic forms
WO2008004000A1 (en) 2006-07-03 2008-01-10 Generics [Uk] Limited Novel process for the preparation of bisphosphonic acids
WO2008065542A2 (en) 2006-09-22 2008-06-05 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for the preparation of risedronate sodium
WO2008044245A2 (en) 2006-10-10 2008-04-17 Matrix Laboratories Ltd A process for the preparation of risedronate sodium hemipentahydrate
PT103600B (en) 2006-11-06 2009-01-30 Hovione Farmaciencia Sa PROCESS FOR THE PREPARATION OF BIOSPHONIC ACIDS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
KR100775440B1 (en) 2006-12-20 2007-11-12 동우신테크 주식회사 Method for preparing risedronate sodium hemipentahydrate
WO2008152518A2 (en) 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
WO2009050731A2 (en) 2007-06-20 2009-04-23 Alkem Laboratories Ltd Novel process for preparing risedronic acid
WO2009003001A2 (en) 2007-06-27 2008-12-31 Dr. Reddy's Laboratories Ltd. Preparation of risedronate sodium hemi-pentahydrate
WO2009034580A1 (en) 2007-09-11 2009-03-19 Fleming Laboratories Limited Improved process for the preparation of risedronate sodium hemipentahydrate
KR100925835B1 (en) 2007-12-07 2009-11-06 동우신테크 주식회사 Process for preparing risedronate sodium anhydride and hydrate
US8026388B2 (en) 2008-07-11 2011-09-27 Synthon Bv Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
EA201270328A1 (en) 2009-08-28 2012-09-28 Синтон Б. В. METHOD OF OBTAINING 1-HYDROXYLKYLIDENE-1,1-DIPHOSPHONE ACIDS

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041148A1 (en) * 2006-07-03 2009-04-01 Generics Ýuk¨Limited Novel process for the preparation of bisphosphonic acids
JP2009269867A (en) * 2008-05-08 2009-11-19 Daito Kk Method for industrially producing risedronic acid
CN104418886A (en) * 2013-09-02 2015-03-18 河南天方药业股份有限公司 Risedronic acid synthesized by one-pot process
CN104418886B (en) * 2013-09-02 2017-04-19 天方药业有限公司 Risedronic acid synthesized by one-pot process

Also Published As

Publication number Publication date
US20090182147A1 (en) 2009-07-16
US8076483B2 (en) 2011-12-13
WO2007132478A3 (en) 2009-06-04
MX2008014248A (en) 2009-02-23
KR20090005206A (en) 2009-01-12
JP2009536639A (en) 2009-10-15
BRPI0710421A2 (en) 2011-08-09
EP2016084A2 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
US7528280B2 (en) Process for the preparation of biphosphonic acids
EP1504012B9 (en) Preparation of biphosphonic acids and salts thereof
WO2007096896A1 (en) An improved process for the preparation of biphosphonic derivatives
US8076483B2 (en) Process for the preparation of pure risedronic acid or salts
JP5015006B2 (en) [1-Hydroxy-2- (3-pyridinyl) ethylidene] bisphosphonic acid and its 2.5 hydrate monosodium salt
KR20020024320A (en) Process for producing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid and its trihydrated monosodium salt
CN105175446B (en) Preparation method of minodronic acid for treating osteoporosis
CA2656053A1 (en) Novel process for the preparation of bisphosphonic acids
JP5220843B2 (en) Multi-step synthesis of ibandronate
WO2008152518A2 (en) Process for the preparation of risedronic acid or risedronate sodium
PL213599B1 (en) Method of obtaining of [1-hydroxy-2-(1H-imidazole-1-yl)-ethylidene] bisphosphonic acid
JP3901321B2 (en) Method for producing riboflavin-5'-phosphate or a sodium salt thereof
EP1798236A1 (en) Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
US7414151B2 (en) Process for manufacture of 4-amino-hydroxybutylidene-1, 1-bisphosphonic acid and its salts
EP2609101B1 (en) Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
JPH11269184A (en) New production of heterocyclic bis(phosphonic acid) derivative
WO2013109198A1 (en) Processes for the preparation of sodium ibandronate monohydrate polymorphs a, b and mixture of polymorphs a with b
WO2007010556A1 (en) Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
JP2022528292A (en) Method for producing polymorph F of sodium neridronate
WO2016024287A1 (en) An improved process for preparing pure minodronic acid and intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736604

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12299615

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2009508675

Country of ref document: JP

Ref document number: MX/A/2008/014248

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087028495

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007736604

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 08131644

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0710421

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081107